Hypoimmunogenic derivatives of induced pluripotent stem cells evade immune rejection in fully immunocompetent allogeneic recipients

By T. Deuse, Xiaomeng Hu, A. Gravina, Dong Wang, G. Tediashvili, C. De, W. Thayer, A. Wahl, J. Garcia, H. Reichenspurner and 3 more. Nature Biotechnology, 2019

650 citations recorded by the source corpus.

Autologous induced pluripotent stem cells (iPSCs) constitute an unlimited cell source for patient-specific cell-based organ repair strategies. However, their generation and subsequent differentiation into specific cells or tissues entail cell line-specific manufacturing challenges and form a lengthy process that precludes acute treatment modalities. These shortcomings could be overcome by using prefabricated allogeneic cell or tissue products, but the vigorous immune response against histo-incompatible cells has prevented the successful implementation of this approach. Here we show that both mouse and human iPSCs lose their immunogenicity when major histocompatibility complex (MHC) class I and II genes are inactivated and CD47 is over-expressed. These hypoimmunogenic iPSCs retain their pluripotent stem cell potential and differentiation capacity. Endothelial cells, smooth muscle cells, and cardiomyocytes derived from hypoimmunogenic mouse or human iPSCs reliably evade immune rejection in fully MHC-mismatched allogeneic recipients and survive long-term without the use of immunosuppression. These findings suggest that hypoimmunogenic cell grafts can be engineered for universal transplantation. Genetic engineering prevents immune rejection of allogeneic cell transplants derived from iPSCs.

Subfields: Immunology, Molecular Biology

View Paper: https://www.semanticscholar.org/paper/6a751da0b0f71367e2eabd084b0f1b4a7d3a45ce

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Molecular Biology

  1. A. Sachinidis
  2. M. Doss

Citations in the corpus